Ardelyx (ARDX) rose 12% on a report that Zydus Lifesciences is in talks to purchase the company. Zydus may seek to acquire ...

As cancer cases climb steadily across India, lower-cost biosimilars like Tishtha could reshape access to life-saving ...

Zydus-lifesciences: Get the latest Zydus-lifesciences news, photos, videos, and podcasts. Explore more for Zydus-lifesciences ...

Zydus has also made its first overseas consumer wellness acquisition, UK-based Comfort Click, for £239 million.

Nivolumab, launched at one-fourth the price of the original drug, is one of the most widely inhibitors used in treating various cancer types including lung, melanoma, kidney and Hodgkin lymphoma ...

Zydus Life may acquire Ardelyx control or buy key molecules, sources said, adding that the company is looking at raising ...

India’s Zydus Lifesciences, an innovation-led life-sciences company with an international presence, has launched the world’s first biosimilar of nivolumab in India under the brand name Tishtha, ...

In exchange, Zydus obtained an exclusive license to produce and commercialize Agenus’ immune-oncology platform in India and ...

Zydus Life stated that it has unveiled the biosimilar under the brand Tishtha™. It can be used for treatment of multiple cancers.

This comes just days after the Delhi High Court’s division bench permitted Zydus Lifesciences to manufacture and sell a ...

Investing.com -- Ardelyx Inc (NASDAQ:ARDX) stock surged 13.7% on Tuesday following reports that Indian pharmaceutical company ...

Zydus launches Tishtha, a cost-effective Nivolumab biosimilar in India, enhancing access to advanced cancer treatment.